A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

Recruiting now · Phase 1

Conditions studied: Healthy Volunteers

In brief

This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the selected BMS-986435 tablet formulation will also be evaluated.

Key facts

Study ID

NCT07226817

Run by

Bristol-Myers Squibb

People needed

140

Starts

2025-11-12

Expected to finish

2026-12-17

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants must have a body weight of ≥ 45 kg and BMI between 18 and 32 kg/m2, inclusive
• Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory assessments
• Participants must have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality at screening, as determined by local transthoracic echocardiogram (TTE) assessment
• Other protocol-defined Inclusion/Exclusion criteria apply

Where it is running

• Quotient Miami — Miami, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.